CL2013000604A1 - Compuestos analogos completamente o parcialmente deuterados de 4-(3-metanosulfonil-fenil)-1-propil-piperidina (pridopidina); composicion farmaceutica que los comprende; y metodo de tratamiento, prevencion o alivio de un trastorno mediado por dopamina. - Google Patents
Compuestos analogos completamente o parcialmente deuterados de 4-(3-metanosulfonil-fenil)-1-propil-piperidina (pridopidina); composicion farmaceutica que los comprende; y metodo de tratamiento, prevencion o alivio de un trastorno mediado por dopamina.Info
- Publication number
- CL2013000604A1 CL2013000604A1 CL2013000604A CL2013000604A CL2013000604A1 CL 2013000604 A1 CL2013000604 A1 CL 2013000604A1 CL 2013000604 A CL2013000604 A CL 2013000604A CL 2013000604 A CL2013000604 A CL 2013000604A CL 2013000604 A1 CL2013000604 A1 CL 2013000604A1
- Authority
- CL
- Chile
- Prior art keywords
- pridopidine
- methanesulfonyl
- dopamine
- piperidine
- relief
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 229950003764 pridopidine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201070385 | 2010-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000604A1 true CL2013000604A1 (es) | 2013-11-15 |
Family
ID=44653278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000604A CL2013000604A1 (es) | 2010-09-03 | 2013-03-01 | Compuestos analogos completamente o parcialmente deuterados de 4-(3-metanosulfonil-fenil)-1-propil-piperidina (pridopidina); composicion farmaceutica que los comprende; y metodo de tratamiento, prevencion o alivio de un trastorno mediado por dopamina. |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20130197031A1 (https=) |
| EP (1) | EP2611759A1 (https=) |
| JP (1) | JP2013536825A (https=) |
| KR (1) | KR20140008297A (https=) |
| CN (1) | CN103249697B (https=) |
| AU (2) | AU2011298382A1 (https=) |
| BR (1) | BR112013005125A2 (https=) |
| CA (1) | CA2810092A1 (https=) |
| CL (1) | CL2013000604A1 (https=) |
| EA (1) | EA201390332A1 (https=) |
| IL (1) | IL224776A (https=) |
| MX (1) | MX2013002453A (https=) |
| NZ (1) | NZ608120A (https=) |
| PE (1) | PE20140105A1 (https=) |
| PH (1) | PH12013500406A1 (https=) |
| SG (2) | SG10201506761XA (https=) |
| WO (1) | WO2012028635A1 (https=) |
| ZA (1) | ZA201301902B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| CN101711236B (zh) * | 2007-04-12 | 2012-10-31 | Nsab神经研究瑞典公司分公司 | 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 |
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| BR112014005389A8 (pt) | 2011-09-07 | 2018-04-03 | Ivax Int Gmbh | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| EP4345100A3 (en) | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| HK1221646A1 (zh) | 2013-06-21 | 2017-06-09 | Teva Pharmaceuticals International Gmbh | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| KR20160117596A (ko) | 2014-02-07 | 2016-10-10 | 오스펙스 파마슈티칼스, 인코포레이티드 | 신규 제약 제제 |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AU2016229949B2 (en) | 2015-03-06 | 2021-04-08 | Auspex Pharmaceuticals Llc | Methods for the treatment of abnormal involuntary movement disorders |
| AR105434A1 (es) * | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| JP7034488B2 (ja) | 2016-02-24 | 2022-03-14 | プリレニア・ニューロセラピューティクス・エルティーディー | プリドピジンを使用する神経変性眼疾患の治療 |
| EP4516356A3 (en) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| CN109952100A (zh) | 2016-09-15 | 2019-06-28 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗焦虑和抑郁的用途 |
| HUE058314T2 (hu) | 2016-09-16 | 2022-07-28 | Prilenia Neurotherapeutics Ltd | Pridopidin alkalmazása Rett-szindróma kezelésére |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| US10459055B2 (en) * | 2017-04-07 | 2019-10-29 | Case Western Reserve University | System and method for reduced field of view MR fingerprinting for parametric mapping |
| SI4154882T1 (sl) | 2017-08-14 | 2026-01-30 | Prilenia Neurotherapeutics Ltd. | Zdravljenje amiotrofične lateralne skleroze s pridopidinom |
| CA3073568A1 (en) | 2017-08-30 | 2019-03-07 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
| JP2020533296A (ja) | 2017-09-08 | 2020-11-19 | プリレニア ニューロセラピューティクス リミテッド | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CN113395964A (zh) | 2019-02-04 | 2021-09-14 | 普瑞尼亚神经治疗有限公司 | 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定 |
| JP7701931B2 (ja) | 2020-02-13 | 2025-07-02 | プリレニア ニューロセラピューティクス リミテッド | プリドピジンおよび他の活性薬剤を使用して筋萎縮性側索を治療するための併用療法 |
| CA3176917A1 (en) | 2020-05-04 | 2021-11-11 | Prilenia Neurotherapeutics Ltd. | Treatment of viral infection, disease or disorder using a selective s1r agonist |
| MX2022014599A (es) * | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| US20230181362A1 (en) | 2020-05-20 | 2023-06-15 | Nthalmic Holding Pty Ltd | Methods and apparatus to manage meibomian gland deficiencies |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
| WO2026080658A1 (en) | 2024-10-10 | 2026-04-16 | Prilenia Therapeutics Inc. | Pridopidine for the treatment of distal hereditary motor neuropathy (dhmn) |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| PT1104760E (pt) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| DE10123129A1 (de) * | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| US7004629B2 (en) | 2003-07-26 | 2006-02-28 | Arthur Joseph Shrader | Method and apparatus for hanging a resealable bag |
| ES2346452T3 (es) | 2004-06-08 | 2010-10-15 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina. |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| EP1934201A1 (en) * | 2005-10-06 | 2008-06-25 | Auspex Pharmaceuticals Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| US20070112031A1 (en) | 2005-11-14 | 2007-05-17 | Gant Thomas G | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| CN101360742A (zh) * | 2005-11-14 | 2009-02-04 | 奥斯拜客斯制药有限公司 | 具有血清素源性活性和增强的治疗特性的取代苯基哌啶 |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| CN101711236B (zh) | 2007-04-12 | 2012-10-31 | Nsab神经研究瑞典公司分公司 | 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物 |
| WO2008155357A2 (en) | 2007-06-18 | 2008-12-24 | A. Carlsson Research Ab | Use of dopamine stabilizers |
| US8288414B2 (en) * | 2007-09-12 | 2012-10-16 | Deuteria Pharmaceuticals, Inc. | Deuterium-enriched lenalidomide |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| JP2013536825A (ja) | 2010-09-03 | 2013-09-26 | イバックス・インターナショナル・ゲーエムベーハー | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 |
| BR112014005389A8 (pt) | 2011-09-07 | 2018-04-03 | Ivax Int Gmbh | Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal |
| TWI579272B (zh) | 2011-12-08 | 2017-04-21 | 梯瓦製藥國際有限責任公司 | 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽 |
| AU2013243461A1 (en) | 2012-04-04 | 2014-11-06 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for combination therapy |
| MX2015003608A (es) | 2012-09-27 | 2015-06-05 | Teva Pharma | Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos. |
| US20150216850A1 (en) | 2012-09-27 | 2015-08-06 | Michael Hayden | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
| HK1221646A1 (zh) | 2013-06-21 | 2017-06-09 | Teva Pharmaceuticals International Gmbh | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| MX377576B (es) | 2014-01-22 | 2025-03-04 | Prilenia Neurotherapeutics Ltd | Formulaciones de pridopidina de liberación modificada. |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
| EP3324967A4 (en) | 2015-07-22 | 2019-03-20 | Prilenia Therapeutics Development Ltd. | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| US20170026730A1 (en) | 2015-07-23 | 2017-01-26 | Knowles Electronics, Llc | Microphone with temperature sensor |
| JP7034488B2 (ja) | 2016-02-24 | 2022-03-14 | プリレニア・ニューロセラピューティクス・エルティーディー | プリドピジンを使用する神経変性眼疾患の治療 |
| EP4516356A3 (en) | 2016-08-24 | 2025-05-14 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating functional decline |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| CN109952100A (zh) | 2016-09-15 | 2019-06-28 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗焦虑和抑郁的用途 |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| CN109906270A (zh) | 2016-09-16 | 2019-06-18 | 嘉吉公司 | 经遗传修饰的乳酸消耗酵母以及使用此类经遗传修饰的酵母的发酵工艺 |
| CA3050700C (en) | 2017-01-20 | 2023-10-03 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of fragile x syndrome |
| SI4154882T1 (sl) | 2017-08-14 | 2026-01-30 | Prilenia Neurotherapeutics Ltd. | Zdravljenje amiotrofične lateralne skleroze s pridopidinom |
| NL2019473B1 (en) | 2017-09-01 | 2019-03-11 | Isobionics B V | Terpene Synthase producing patchoulol and elemol, and preferably also pogostol |
| JP2020533296A (ja) | 2017-09-08 | 2020-11-19 | プリレニア ニューロセラピューティクス リミテッド | 薬物誘発性ジスキネジアを治療するためのプリドピジン |
-
2011
- 2011-08-31 JP JP2013526452A patent/JP2013536825A/ja active Pending
- 2011-08-31 MX MX2013002453A patent/MX2013002453A/es active IP Right Grant
- 2011-08-31 EA EA201390332A patent/EA201390332A1/ru unknown
- 2011-08-31 WO PCT/EP2011/064954 patent/WO2012028635A1/en not_active Ceased
- 2011-08-31 SG SG10201506761XA patent/SG10201506761XA/en unknown
- 2011-08-31 NZ NZ60812011A patent/NZ608120A/en not_active IP Right Cessation
- 2011-08-31 PH PH1/2013/500406A patent/PH12013500406A1/en unknown
- 2011-08-31 EP EP20110757801 patent/EP2611759A1/en not_active Withdrawn
- 2011-08-31 CN CN201180042460.5A patent/CN103249697B/zh active Active
- 2011-08-31 BR BR112013005125A patent/BR112013005125A2/pt not_active IP Right Cessation
- 2011-08-31 SG SG2013014022A patent/SG188298A1/en unknown
- 2011-08-31 CA CA 2810092 patent/CA2810092A1/en not_active Abandoned
- 2011-08-31 KR KR20137007971A patent/KR20140008297A/ko not_active Ceased
- 2011-08-31 PE PE2013000359A patent/PE20140105A1/es not_active Application Discontinuation
- 2011-08-31 AU AU2011298382A patent/AU2011298382A1/en not_active Abandoned
- 2011-08-31 US US13/820,024 patent/US20130197031A1/en not_active Abandoned
-
2013
- 2013-02-18 IL IL224776A patent/IL224776A/en not_active IP Right Cessation
- 2013-03-01 CL CL2013000604A patent/CL2013000604A1/es unknown
- 2013-03-13 ZA ZA2013/01902A patent/ZA201301902B/en unknown
-
2015
- 2015-12-14 US US14/968,522 patent/US20160166559A1/en not_active Abandoned
- 2015-12-14 US US14/968,510 patent/US20160095847A1/en not_active Abandoned
-
2016
- 2016-10-26 AU AU2016250390A patent/AU2016250390A1/en not_active Abandoned
-
2018
- 2018-04-23 US US15/960,041 patent/US20180235950A1/en not_active Abandoned
- 2018-09-17 US US16/133,192 patent/US10799492B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140008297A (ko) | 2014-01-21 |
| NZ608120A (en) | 2014-12-24 |
| US20130197031A1 (en) | 2013-08-01 |
| JP2013536825A (ja) | 2013-09-26 |
| AU2016250390A1 (en) | 2016-11-10 |
| WO2012028635A1 (en) | 2012-03-08 |
| US10799492B2 (en) | 2020-10-13 |
| US20190015401A1 (en) | 2019-01-17 |
| PE20140105A1 (es) | 2014-02-14 |
| MX2013002453A (es) | 2013-08-01 |
| EA201390332A1 (ru) | 2013-08-30 |
| ZA201301902B (en) | 2014-05-28 |
| US20160095847A1 (en) | 2016-04-07 |
| EP2611759A1 (en) | 2013-07-10 |
| BR112013005125A2 (pt) | 2016-08-16 |
| IL224776A (en) | 2017-07-31 |
| SG10201506761XA (en) | 2015-10-29 |
| US20160166559A1 (en) | 2016-06-16 |
| AU2011298382A1 (en) | 2013-05-02 |
| CN103249697B (zh) | 2016-06-15 |
| PH12013500406A1 (en) | 2019-07-17 |
| US20180235950A1 (en) | 2018-08-23 |
| CN103249697A (zh) | 2013-08-14 |
| CA2810092A1 (en) | 2012-03-08 |
| SG188298A1 (en) | 2013-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000604A1 (es) | Compuestos analogos completamente o parcialmente deuterados de 4-(3-metanosulfonil-fenil)-1-propil-piperidina (pridopidina); composicion farmaceutica que los comprende; y metodo de tratamiento, prevencion o alivio de un trastorno mediado por dopamina. | |
| MX2011013739A (es) | Composiciones y metodos para reducir trigliceridos sin elevar los niveles de ldl-c en un sujeto en terapia de estatina concomitante. | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| DK2532366T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| CR20120008A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2014001065A1 (es) | Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer. | |
| BR112015000437A2 (pt) | imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula | |
| BR112015001838A2 (pt) | composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo. | |
| DK2818481T3 (da) | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer | |
| CL2014002640A1 (es) | Compuestos pirrolidin, piperidin o azepan sustituidos, inhibidores de met-ap2; procedimiento para prepararlos; y medicamento que los contiene. | |
| BR112015007214A8 (pt) | composto, método para a inibição da atividade da quinase, método para o tratamento, composição, utilização de um composto e invenção | |
| DK2632954T4 (da) | Midler og fremgangsmåder til behandling af dlbcl | |
| DOP2013000195A (es) | Compuestos novedosos en base a ureas asimetricas, y usos medicos de los mismos | |
| CL2015001753A1 (es) | Compuestos derivados de carbamato de ciclohexilo y quinuclidinilo, agonistas beta2 adrenergicos y antagonistas muscarinicos m3; composicion farmaceutica que los comprende; metodo para tratar; y producto de combinacion que comprende a estos compuestos junto a un corticosteroide y/o un inhibidor de pde4. | |
| BRPI1015983A2 (pt) | composto, uso do composto, método para tratar um paciente, e, composição farmacêutica. | |
| BR112014030416A2 (pt) | composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção. | |
| BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
| DK2467364T3 (da) | Nitrogen-holdige forbindelser og farmaceutiske sammensætninger for behandling af atrial flimren. | |
| CL2014003429A1 (es) | Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia. | |
| ITTO20110630A1 (it) | Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa | |
| CL2015000732A1 (es) | Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica. | |
| BR112015001843A2 (pt) | dispositivo médico, composição de matriz biodegradável e método para tratar um paciente. | |
| BR112014023344A2 (pt) | Composição de barra de sabão e método para o fornecimento da redução dos germes | |
| PH12015502706B1 (en) | Oral formulation for the treatment of cardiovascular diseases | |
| BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose |